推荐产品
等級
pharmaceutical primary standard
agency
EP Reference standard
API 家族
metformin
製造商／商標名
EDQM
mp
223-226 °C (lit.)
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
Cl[H].CN(C)C(=N)NC(N)=N
InChI
1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H
InChI 密鑰
OETHQSJEHLVLGH-UHFFFAOYSA-N
基因資訊
正在寻找类似产品? 访问 产品对比指南
相关类别
相關產品
产品编号
说明
价格
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Eye Irrit. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Yen-Hsiang Chang et al.
Frontiers in endocrinology, 11, 445-445 (2020-08-28)
Background: Plenty of evidence suggested that chronic low-grade inflammation triggered by innate immunity activation contributes to the pathogenesis of type 2 diabetes (T2D). Using the trans-mitochondrial cybrid cell model, we have demonstrated that mitochondria independently take part in the pathological
L C Morin-Papunen et al.
The Journal of clinical endocrinology and metabolism, 85(9), 3161-3168 (2000-09-22)
Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial. Oral contraceptive pills are commonly used in the
P H Marathe et al.
British journal of clinical pharmacology, 50(4), 325-332 (2000-09-30)
The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. An open-label, three treatment, three period crossover study was conducted in 11
J De Jager et al.
Journal of internal medicine, 257(1), 100-109 (2004-12-21)
The UK Prospective Diabetes Study (UKPDS) showed that treatment with metformin decreases macrovascular morbidity and mortality independent of glycaemic control. We hypothesized that metformin may achieve this by improving endothelial function and chronic, low-grade inflammation. Data on this issue are
P S Gillies et al.
Drugs, 60(2), 333-343 (2000-09-13)
Pioglitazone is an orally administered insulin sensitising thiazolidinedione agent that has been developed for the treatment of type 2 diabetes mellitus. Pioglitazone activates the nuclear peroxisome proliferator activated receptor-gamma (PPAR-gamma), which leads to the increased transcription of various proteins regulating
实验方案
Separation of Melamine; 1,1-Dimethylbiguanide hydrochloride
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门